Updates are available Correction dated 2023-03-13
Click to view Correction: https://doi.org/10.1186/s13023-023-02646-0
-
Authors
Shelkowitz, Emily
Saneto, Russell P.
Al-Hertani, Walla
Lubout, Charlotte M. A.
Stence, Nicholas V.
Brown, Mark S.
Long, Patrick
Walleigh, Diana
Nelson, Julie A.
Perez, Francisco E.
Shaw, Dennis W. W.
Michl, Emma J.
Van Hove, Johan L. K. https://orcid.org/0000-0003-2850-3294
-
Funding
Funding for this research was provided by:
NKH Crusaders
Hope for NKH Foundation
Brodyn's Friends
Nora Jane Almany Foundation
Dickens Family Foundation
Les Petits Bourdons
Lucas John Foundation
Jacqueline Kirby Foundation
University of Colorado Foundation (NKH Research Fund)
- License Information
-
More Information
Article History
Received: 26 August 2022
Accepted: 20 November 2022
First Online: 5 December 2022
Change Date: 13 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-023-02646-0
Declarations
:
: The study was performed under an IRB-approved protocol (Colorado COMIRB# 05-0790) for nonketotic hyperglycinemia patients. Informed consent was obtained from all living subjects. Per institutional rule, no further ethics committee review was required for the patient at the Groningen center. Consent for publication was received from all families. All procedures were done in accordance with the ethical standards of the ethics committee in accordance with the Helsinki Declaration of 1975 and as revised in 2000.
: Consent for publication was received from all families. All procedures were done in accordance with the ethical standards of the ethics committee in accordance with the Helsinki Declaration of 1975 and as revised in 2000.
: The University of Colorado (JVH) has a pending patent application to the use of formate for the treatment of conditions associated with elevated homocysteine. All authors further deny any real or apparent conflict of interest pertaining to nonketotic hyperglycinemia.
